Supplements

Ion channel modulators, particularly calcium channel blockers and sodium channel antagonists, reduce pain and improve sleep in patients with painful diabetic neuropathy

A meta-analysis of 36 RCTs with 6611 participants found that ion channel modulators, especially calcium channel blockers (mirogabalin, pregabalin, gabapentin, crisugabalin) and sodium channel antagonists (oxcarbazepine, lacosamide, lamotrigine, sodium valproate), significantly reduced pain scores, VAS scores, and sleep interference scores compared to placebo. TRPA1 and P2X3 antagonists showed no significant difference from control. Adverse events were mild to moderate, though mirogabalin and oxcarbazepine had higher discontinuation risk.

Last updated: Jul 11, 2026•0 RCTs•1 Meta-analyses•📖 Read as article →

Evidence Score

Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.

observational

Li D, Ouyang L, Chen Z, Long Y, Deng G · Diabetes, obesity & metabolism (2026)

Participants: N/A
Duration: N/A
Intervention: Ion channel modulators including calcium channel blockers, sodium channel blockers, TRPA1 antagonists, and P2X3 antagonists
Outcome: Pain score, VAS score, 30% and 50% pain reduction, PGIC, sleep interference score, adverse events, treatment discontinuation
Effect Size: N/A (specific effect sizes not reported in abstract)
Population: 6611 participants with painful diabetic neuropathy (PDN) from 36 RCTs

Result:

PubMed: 42417183DOI: 10.1111/dom.71053

Mechanism Graph

Ion channel modulators bind to voltage-gated calcium or sodium channels in peripheral nerves
↓
Modulation reduces aberrant neuronal excitability and ectopic firing
↓
Decreased neurotransmitter release and pain signal transmission
↓
Result: Reduced pain perception and improved sleep quality

Limitations

  • ⚠Abstract does not report specific effect sizes or confidence intervals for primary outcomes
  • ⚠Heterogeneity among studies was quantified but not described in detail, potentially affecting generalizability
  • ⚠Only one RCT each for TRPA1 and P2X3 antagonists, limiting conclusions about these classes

Frequently Asked Questions

Which ion channel modulators are most effective for painful diabetic neuropathy?▼

Calcium channel blockers (mirogabalin, pregabalin, gabapentin, crisugabalin) and sodium channel antagonists (oxcarbazepine, lacosamide, lamotrigine, sodium valproate) showed significant pain reduction, while TRPA1 and P2X3 antagonists did not differ from placebo.

Do these drugs improve sleep in PDN patients?▼

Yes, the meta-analysis found that calcium channel blockers and sodium channel antagonists significantly reduced sleep interference scores compared to placebo.

What are the safety concerns with these medications?▼

Adverse events were mild to moderate and generally well tolerated, but mirogabalin and oxcarbazepine had a higher risk of treatment discontinuation due to adverse events.

How many patients were included in this analysis?▼

The meta-analysis included 36 randomized controlled trials with a total of 6611 participants with painful diabetic neuropathy.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Li D, Ouyang L, Chen Z, Long Y, Deng G. "Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.." Diabetes, obesity & metabolism, 2026. PMID: 42417183 DOI: 10.1111/dom.71053
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.